& dated that is still relevant--- '09 Genentech contradiction, resembles the Remdesivir issues. The SC ruling protected them to flip & change things on the fly.

Genentech, Wyeth, Senator questioning FDA on practices, long before covid.

Pre-covid, during covid, they haven't understood MAB/Cytolin/Leronlimab.

Yep, you're right about their "perception", because in the emails, I think it was Suzzane reply to Murray, re r. J --- if he thinks it's an immunosuppressive, it's a problem.

That was not even close to what Dr. J was saying.
The Supreme Court ruling allows them to be sloppy, slow or flat out not give effort.

I'm going to stay in a happy mindset of our 2024 FDA dealings, like Dr. J is. Topped off with MGK_2 reminding pharma has no head to head weapon.

From a historical Letter, to a historical lift, I'm optimistic your list of 90, turns into reality.
________
"For example, if someone is injured by a dangerous or defective drug that was approved by the FDA, they can still sue. However, the FDA is viewed as a regulatory body or gatekeeper, so the complaint should be directed at the company that made the bad product."


https://www.fiercebiotech.com/biotech/cytodyn...rug-safety

https://blogs.kentlaw.iit.edu/islat/2009/03/1...-it-right/